{"id":"artesunate","rwe":[],"tags":[{"label":"artesunate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P01BE03","category":"atc"},{"label":"Active","category":"status"},{"label":"Falciparum malaria","category":"indication"},{"label":"Vivax malaria","category":"indication"},{"label":"Amivas","category":"company"},{"label":"Approved 2020s","category":"decade"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiplatyhelmintic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Schistosomicides","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":237.294,"date":"","count":46,"signal":"Haemolytic anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=237)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Amivas","patents":[{"applNo":"N213036","source":"FDA Orange Book","status":"Active","expires":"Feb 16, 2044","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12121506","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T16:33:20.730329","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ARTESUNATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:06:42.221746+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:06:42.221334+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:06:50.178587+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:06:42.246070+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTESUNATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:06:51.928272+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL361497/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:06:52.401316+00:00"}},"allNames":["artesunate","arinate","arsuamoon","arsumax","artesunic acid","cosunate","dihydroqinghasu hemsuccinate","artesunate amivas"],"offLabel":[],"synonyms":["artesunate","arinate","arsuamoon","arsumax","artesunic acid","cosunate","dihydroqinghasu hemsuccinate","artesunate amivas"],"timeline":[{"date":"2020-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from AMIVAS to Amivas"},{"date":"2020-05-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Amivas)"},{"date":"2021-11-22","type":"positive","source":"DrugCentral","milestone":"EMA approval (Amivas Ireland Ltd)"},{"date":"2027-05-26","type":"negative","source":"FDA Orange Book","milestone":"ODE-290 exclusivity expires"}],"brandName":"Artesunate","ecosystem":[{"indication":"Falciparum malaria","otherDrugs":[{"name":"atovaquone","slug":"atovaquone","company":""},{"name":"chloroquine","slug":"chloroquine","company":"Sanofi Aventis Us"},{"name":"halofantrine","slug":"halofantrine","company":"Glaxosmithkline"},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Vivax malaria","otherDrugs":[{"name":"chloroquine","slug":"chloroquine","company":"Sanofi Aventis Us"},{"name":"halofantrine","slug":"halofantrine","company":"Glaxosmithkline"},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"},{"name":"mefloquine","slug":"mefloquine","company":""}],"globalPrevalence":240000}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"artesunate","explanation":"","oneSentence":"","technicalDetail":"Artesunate is a heme polymerase inhibitor that targets the malaria parasite's heme detoxification pathway, leading to the accumulation of toxic heme and ultimately, parasite death."},"commercial":{"launchDate":"2020","_launchSource":"DrugCentral (FDA 2020-05-26, AMIVAS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/247","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ARTESUNATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTESUNATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:45:49.898734","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:54.306285+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"artemether","drugSlug":"artemether","fdaApproval":"2009-04-07","relationship":"same-class"}],"exclusivity":[{"code":"ODE-290","date":"May 26, 2027"}],"genericName":"artesunate","indications":{"approved":[{"name":"Falciparum malaria","source":"DrugCentral","snomedId":62676009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Vivax malaria","source":"DrugCentral","snomedId":27052006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(4162)"],"currentOwner":"Amivas","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"artemether","brandName":"artemether","genericName":"artemether","approvalYear":"2009","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06923592","phase":"PHASE3","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-05-12","conditions":["Malaria Vivax","Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum"],"enrollment":19200,"completionDate":"2027-04-28"},{"nctId":"NCT07060794","phase":"PHASE4","title":"Tafenoquine and ACTs (TADORE- Plus)","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06","conditions":["Vivax Malaria"],"enrollment":507,"completionDate":"2028-06"},{"nctId":"NCT07470424","phase":"PHASE1","title":"A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06-01","conditions":["Malaria"],"enrollment":24,"completionDate":"2027-08-01"},{"nctId":"NCT06967519","phase":"PHASE4","title":"OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-18","conditions":["Malaria","Hiv"],"enrollment":380,"completionDate":"2027-12"},{"nctId":"NCT06806956","phase":"","title":"Severe Malaria in Remote Areas- Closing the Evidence Gap","status":"ENROLLING_BY_INVITATION","sponsor":"Tropical Diseases Research Centre, Zambia","startDate":"2024-03-10","conditions":["Severe Malaria"],"enrollment":2016,"completionDate":"2027-04"},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":["Malaria Falciparum"],"enrollment":316,"completionDate":"2024-01-31"},{"nctId":"NCT05988463","phase":"PHASE1","title":"Dose-Escalation Study of Artesunate Patients With IPF","status":"RECRUITING","sponsor":"Joseph C. Wu","startDate":"2027-01-01","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":15,"completionDate":"2028-11-01"},{"nctId":"NCT06872112","phase":"PHASE1","title":"A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"Joseph C. Wu","startDate":"2026-01-01","conditions":["Pulmonary Arterial Hypertension (PAH)"],"enrollment":15,"completionDate":"2029-01-01"},{"nctId":"NCT05750459","phase":"PHASE4","title":"Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-29","conditions":["Plasmodium Falciparum Infection"],"enrollment":90,"completionDate":"2025-04-01"},{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":["Severe Malaria"],"enrollment":254,"completionDate":"2025-08-20"},{"nctId":"NCT06519994","phase":"PHASE2","title":"Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-22","conditions":["Human Immunodeficiency Virus","Human Papillomavirus","Cervical Precancer"],"enrollment":120,"completionDate":"2026-04-08"},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":["Malaria, Pregnancy","Malaria, Antepartum","Malaria (Uncomplicated)"],"enrollment":1510,"completionDate":"2029-08"},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":1680,"completionDate":"2026-07-31"},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":["Plasmodium Falciparum Malaria (Uncomplicated)"],"enrollment":2583,"completionDate":"2024-03-15"},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":["Plasmodium Vivax Malaria","Malaria"],"enrollment":7530,"completionDate":"2027-05-01"},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":["CMV Infection"],"enrollment":90,"completionDate":"2028-06-30"},{"nctId":"NCT04098744","phase":"PHASE2","title":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2020-09-09","conditions":["CIN 2/3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease"],"enrollment":78,"completionDate":"2026-12-31"},{"nctId":"NCT07022743","phase":"PHASE2","title":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Obafemi Awolowo University","startDate":"2025-07-01","conditions":["Chronic Myeloid Leukemia (CML)"],"enrollment":75,"completionDate":"2026-12"},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":["Malaria"],"enrollment":870,"completionDate":"2025-07-30"},{"nctId":"NCT06263582","phase":"PHASE1","title":"Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-05-29","conditions":["Cervix Cancer","Cervix Intraepithelial Neoplasia Grade 3","Cervix; Intraepithelial Neoplasia, Grade I","Cervix; Intraepithelial Neoplasia, Grade II"],"enrollment":12,"completionDate":"2024-08-14"},{"nctId":"NCT06165614","phase":"PHASE1","title":"Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-03-04","conditions":["Cervix Cancer","Cervix Neoplasm","Precancerous Conditions","Cervical Precancer"],"enrollment":17,"completionDate":"2025-04-10"},{"nctId":"NCT06075264","phase":"PHASE2","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-12-06","conditions":["Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia"],"enrollment":27,"completionDate":"2027-12"},{"nctId":"NCT07095309","phase":"PHASE2","title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Metanoic Health Ltd.","startDate":"2025-08-15","conditions":["Stage II/III Colon Cancer","Bowel Cancer"],"enrollment":120,"completionDate":"2033-07-31"},{"nctId":"NCT07095478","phase":"PHASE2","title":"Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Metanoic Health Ltd.","startDate":"2025-08-01","conditions":["CIN 2/3"],"enrollment":28,"completionDate":"2028-06-30"},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":["COVID-19"],"enrollment":192,"completionDate":"2021-08-23"},{"nctId":"NCT05555862","phase":"PHASE2","title":"Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-02-10","conditions":["Anal High Grade Squamous Intraepithelial Lesion","Anal Precancerous Condition","AIN 2/3","HPV Infection","Anal Dysplasia","HPV Disease"],"enrollment":17,"completionDate":"2026-12-31"},{"nctId":"NCT06206564","phase":"PHASE2","title":"Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2024-01-12","conditions":["Anal High-grade Squamous Intraepithelial Lesion","Anal HSIL","Anal HPV Infection","AIN"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT04706130","phase":"PHASE4","title":"Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-15","conditions":["Vivax Malaria"],"enrollment":160,"completionDate":"2024-10-01"},{"nctId":"NCT03300648","phase":"PHASE3","title":"Treating Brain Swelling in Pediatric Cerebral Malaria","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2018-01-08","conditions":["Malaria, Cerebral"],"enrollment":57,"completionDate":"2023-12-31"},{"nctId":"NCT06173206","phase":"PHASE3","title":"Parasite Clearance and Protection from Infection (PCPI) in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-06-10","conditions":["Malaria"],"enrollment":902,"completionDate":"2025-03-05"},{"nctId":"NCT06166498","phase":"PHASE3","title":"Parasite Clearance and Protection From Infection (PCPI) in Zambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-07-24","conditions":["Malaria"],"enrollment":600,"completionDate":"2025-03-05"},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":["Malaria"],"enrollment":16,"completionDate":"2025-01-06"},{"nctId":"NCT05764746","phase":"PHASE2,PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":384,"completionDate":"2024-12-30"},{"nctId":"NCT06555809","phase":"","title":"Evaluation of Artesunate in Infants Being Treated for Severe Malaria","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2024-10-06","conditions":["Malaria"],"enrollment":15,"completionDate":"2030-02-28"},{"nctId":"NCT05441410","phase":"PHASE1,PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":["Malaria"],"enrollment":30,"completionDate":"2026-06-30"},{"nctId":"NCT03792516","phase":"PHASE1","title":"Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":["Vulvar Dysplasia","HPV-Related Vulvar Intraepithelial Neoplasia","Preinvasive Vulvar Disease","Vulva Intraepithelial Neoplasia","Vulvar Diseases"],"enrollment":15,"completionDate":"2024-12-03"},{"nctId":"NCT03640403","phase":"PHASE3","title":"Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2019-03-26","conditions":["Malaria,Falciparum","Anemia"],"enrollment":1555,"completionDate":"2021-12-31"},{"nctId":"NCT06076213","phase":"PHASE4","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2023-05-01","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":1260,"completionDate":"2024-09-30"},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":["Malaria,Falciparum"],"enrollment":100,"completionDate":"2023-01-26"},{"nctId":"NCT04921930","phase":"PHASE1,PHASE2","title":"Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-05-06","conditions":["Friedreich Ataxia"],"enrollment":20,"completionDate":"2024-04-17"},{"nctId":"NCT06472258","phase":"NA","title":"Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2023-03-01","conditions":["Malaria"],"enrollment":104,"completionDate":"2023-06-30"},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":["Plasmodium Falciparum","Malaria","Uncomplicated Malaria"],"enrollment":352,"completionDate":"2023-08-16"},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":["Plasmodium Falciparum Malaria (Uncomplicated)"],"enrollment":103,"completionDate":"2023-01-28"},{"nctId":"NCT05140278","phase":"PHASE2","title":"Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-18","conditions":["Severe Malaria"],"enrollment":200,"completionDate":"2023-08-11"},{"nctId":"NCT00616304","phase":"PHASE2","title":"Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria","status":"SUSPENDED","sponsor":"Menzies School of Health Research","startDate":"2008-02","conditions":["Severe Falciparum Malaria"],"enrollment":8,"completionDate":""},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":["Covid-19","Malaria"],"enrollment":143,"completionDate":"2024-02-20"},{"nctId":"NCT05285735","phase":"","title":"Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2022-06-08","conditions":["Pregnancy","Malaria"],"enrollment":25,"completionDate":"2029-07-01"},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":["Malaria"],"enrollment":60,"completionDate":"2014-01"},{"nctId":"NCT01523002","phase":"PHASE1","title":"Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-01","conditions":["Malaria"],"enrollment":56,"completionDate":"2012-10"},{"nctId":"NCT04330690","phase":"PHASE3","title":"Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-03-18","conditions":["COVID-19"],"enrollment":2900,"completionDate":"2024-05-18"},{"nctId":"NCT05929157","phase":"PHASE1,PHASE2","title":"A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate","status":"UNKNOWN","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2023-09-01","conditions":["Severe Malarial Treatment"],"enrollment":12,"completionDate":"2025-06-30"},{"nctId":"NCT02786589","phase":"PHASE1,PHASE2","title":"Plasmodium Immunotherapy for Lung Cancer","status":"UNKNOWN","sponsor":"State Key Laboratory of Respiratory Disease","startDate":"2016-06-27","conditions":["Lung Cancer, Nonsmall Cell"],"enrollment":30,"completionDate":"2023-12-30"},{"nctId":"NCT05084911","phase":"PHASE3","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-10-18","conditions":["COVID-19"],"enrollment":1807,"completionDate":"2023-03-24"},{"nctId":"NCT04713631","phase":"PHASE2","title":"Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease","status":"UNKNOWN","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2021-01-21","conditions":["Crohn's Disease"],"enrollment":40,"completionDate":"2024-01"},{"nctId":"NCT00682630","phase":"PHASE1","title":"Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09","conditions":["Malaria"],"enrollment":42,"completionDate":"2008-09"},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":["Malaria"],"enrollment":34,"completionDate":"2010-09"},{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":["P. Falciparum Malaria"],"enrollment":76,"completionDate":"2017-03-30"},{"nctId":"NCT05633420","phase":"PHASE2","title":"Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-07-24","conditions":["COVID-19"],"enrollment":20,"completionDate":"2022-11-20"},{"nctId":"NCT04783051","phase":"PHASE3","title":"Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)","status":"COMPLETED","sponsor":"University of Kinshasa","startDate":"2021-05-06","conditions":["Malaria in Pregnancy"],"enrollment":250,"completionDate":"2022-06-22"},{"nctId":"NCT02633098","phase":"PHASE2","title":"A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2017-04-26","conditions":["Colorectal Cancer","Bowel Cancer"],"enrollment":200,"completionDate":"2025-10-31"},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":60,"completionDate":"2006-12"},{"nctId":"NCT04387240","phase":"PHASE2","title":"Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19","status":"WITHDRAWN","sponsor":"Princess Nourah Bint Abdulrahman University","startDate":"2022-01","conditions":["Covid 19 Positive","Corona Virus Infection"],"enrollment":0,"completionDate":"2022-12"},{"nctId":"NCT05192265","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":["Malaria Fever","Plasmodium Falciparum Malaria","Uncomplicated Malaria"],"enrollment":172,"completionDate":"2020-12-23"},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":["Plasmodium Falciparum Malaria","Plasmodium Vivax Malaria"],"enrollment":49118,"completionDate":"2022-03-31"},{"nctId":"NCT04265573","phase":"","title":"Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies","status":"COMPLETED","sponsor":"Groupe de Recherche Action en Sante","startDate":"2018-11-10","conditions":["Malaria"],"enrollment":150000,"completionDate":"2021-02-25"},{"nctId":"NCT05273242","phase":"PHASE4","title":"Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-12-06","conditions":["COVID-19"],"enrollment":400,"completionDate":"2022-12"},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":["Malaria"],"enrollment":511,"completionDate":"2016-09"},{"nctId":"NCT04516317","phase":"","title":"Very Severe Malaria Treated by Intravenous Artesunate","status":"COMPLETED","sponsor":"Dr Fabrice BRUNEEL","startDate":"2020-08-10","conditions":["Severe Malaria"],"enrollment":578,"completionDate":"2022-03-22"},{"nctId":"NCT03568344","phase":"","title":"Community Access to Rectal Artesunate for Malaria","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2018-06-15","conditions":["Malaria"],"enrollment":13758,"completionDate":"2021-08-31"},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":["Malaria"],"enrollment":1117,"completionDate":"2022-02-08"},{"nctId":"NCT05223933","phase":"NA","title":"Proactive Community Case Management (Pro-CCM) in Rural Madagascar","status":"COMPLETED","sponsor":"Institut Pasteur de Madagascar","startDate":"2016-12-12","conditions":["Malaria","Case Management"],"enrollment":1000,"completionDate":"2018-12-29"},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":["Malaria"],"enrollment":30,"completionDate":"2010-11-15"},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":["COVID","Sars-CoV2"],"enrollment":13,"completionDate":"2022-01-12"},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":["Malaria"],"enrollment":535,"completionDate":"2008-11"},{"nctId":"NCT03100045","phase":"PHASE1","title":"Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-04-20","conditions":["HPV-Related Anal Intraepithelial Neoplasia","AIN2/3","Artesunate","Alternative Treatment","Anal Dysplasia","Precancerous Conditions","Human Papilloma Virus"],"enrollment":18,"completionDate":"2021-10-06"},{"nctId":"NCT00440999","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-03","conditions":["Malaria"],"enrollment":456,"completionDate":"2008-09"},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":["Malaria"],"enrollment":1272,"completionDate":"2008-05"},{"nctId":"NCT01594931","phase":"PHASE2","title":"Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2005-07","conditions":["Plasmodium Falciparum Malaria"],"enrollment":477,"completionDate":"2006-04"},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":["Falciparum Malaria"],"enrollment":1271,"completionDate":"2008-12"},{"nctId":"NCT00356824","phase":"","title":"Relationship Between HIV and Malaria in Ugandan Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11","conditions":["HIV Infections","Malaria"],"enrollment":300,"completionDate":"2010-05"},{"nctId":"NCT02304289","phase":"PHASE1","title":"Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2014-11","conditions":["Hepatocellular Carcinoma"],"enrollment":2,"completionDate":"2016-12"},{"nctId":"NCT04701606","phase":"PHASE2,PHASE3","title":"The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-03-29","conditions":["Covid19"],"enrollment":402,"completionDate":"2022-04-15"},{"nctId":"NCT03214731","phase":"PHASE4","title":"Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-01-16","conditions":["Lupus Nephritis"],"enrollment":90,"completionDate":"2022-09-30"},{"nctId":"NCT00297882","phase":"PHASE3","title":"Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":["Malaria"],"enrollment":816,"completionDate":"2009-07"},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":["Malaria"],"enrollment":55,"completionDate":"2019-06-26"},{"nctId":"NCT04475107","phase":"PHASE2","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-07-09","conditions":["COVID-19"],"enrollment":113,"completionDate":"2021-04-15"},{"nctId":"NCT04877626","phase":"PHASE4","title":"Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2008-09","conditions":["P. Falciparum Malaria"],"enrollment":210,"completionDate":"2009-12"},{"nctId":"NCT02084602","phase":"PHASE4","title":"Assessment of Artesunate/Mefloquine in the Peruvian Amazon","status":"COMPLETED","sponsor":"Instituto Nacional de Salud. Peru","startDate":"2014-06-18","conditions":["Malaria, Falciparum"],"enrollment":45,"completionDate":"2016-04-13"},{"nctId":"NCT02354534","phase":"PHASE1","title":"Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":["Cervical Intraepithelial Neoplasia Grade 2/3","High-risk HPV (Any Strain)"],"enrollment":30,"completionDate":"2018-11-06"},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":["Malaria"],"enrollment":409,"completionDate":"2018-07-03"},{"nctId":"NCT03893097","phase":"PHASE3","title":"Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-10-14","conditions":["Schistosoma Haematobium","Schistosoma Mansoni"],"enrollment":726,"completionDate":"2021-03-04"},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":["Falciparum Malaria"],"enrollment":184,"completionDate":"2021-12-31"},{"nctId":"NCT04565184","phase":"PHASE4","title":"Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2019-05-09","conditions":["Malaria,Falciparum"],"enrollment":242,"completionDate":"2020-11-30"},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":["Malaria","Burkina Faso"],"enrollment":1050,"completionDate":"2022-06-01"},{"nctId":"NCT02297477","phase":"PHASE4","title":"The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2014-12","conditions":["Malaria"],"enrollment":205,"completionDate":"2021-12"},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":["Malaria","Parasitic Diseases"],"enrollment":1050,"completionDate":"2021-12"},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":["Plasmodium Falciparum Malaria (Drug Resistant)"],"enrollment":252,"completionDate":"2022-12-30"},{"nctId":"NCT01707199","phase":"NA","title":"SPK Study in Afghanistan","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-10","conditions":["Uncomplicated P. Falciparum Malaria"],"enrollment":83,"completionDate":"2014-01"},{"nctId":"NCT00123552","phase":"PHASE3","title":"Longitudinal Antimalarial Combinations in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":["Malaria"],"enrollment":601,"completionDate":"2008-12"},{"nctId":"NCT02671175","phase":"PHASE3","title":"Post-discharge Malaria Chemoprevention(PMC) Study","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2016-05-20","conditions":["Malaria","Severe Anemia"],"enrollment":1049,"completionDate":"2018-12-12"}],"_emaApprovals":[{"date":"2021-11-22","status":"Authorised","company":"AMIVAS IRELAND LTD"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179045","MMSL":"228453","NDDF":"009953","UNII":"60W3249T9M","VUID":"4025235","CHEBI":"CHEBI:63918","VANDF":"4025235","INN_ID":"6459","RXNORM":"18346","UMLSCUI":"C0052432","chemblId":"CHEMBL361497","ChEMBL_ID":"CHEMBL361497","KEGG_DRUG":"D02482","DRUGBANK_ID":"DB09274","PDB_CHEM_ID":" D95","PUBCHEM_CID":"6917864","SNOMEDCT_US":"432410005","IUPHAR_LIGAND_ID":"9956","MESH_DESCRIPTOR_UI":"D000077332","MESH_SUPPLEMENTAL_RECORD_UI":"C111789"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Amivas","relationship":"Original Developer"},{"period":"2021","companyName":"Amivas Ireland Ltd","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.22 hours","clearance":"1070.0 mL/min/kg","fractionUnbound":"0.25%","volumeOfDistribution":"15.0 L/kg"},"publicationCount":4177,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BE03","allCodes":["P01BE03","P01BF02","P01BF03","P01BF04","P01BF06","P01BF09"]},"biosimilarFilings":[],"originalDeveloper":"Amivas","recentPublications":[{"date":"2026 Mar 27","pmid":"41903303","title":"Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway.","journal":"International immunopharmacology"},{"date":"2026 Mar 20","pmid":"41899312","title":"Clinical Characteristics and Outcomes of Hospitalized Malaria Patients in Rural Madagascar.","journal":"Journal of clinical medicine"},{"date":"2026 Feb","pmid":"41883905","title":"Disseminated Intravascular Coagulation With a Predominant Thrombotic Phenotype in Severe Plasmodium falciparum Malaria: A Case Report.","journal":"Cureus"},{"date":"2026","pmid":"41878271","title":"Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda.","journal":"Drug, healthcare and patient safety"},{"date":"2026","pmid":"41869340","title":"Tunable CAR-NK-92 activity in the tumor microenvironment via a dual ATF4-responsive circuit.","journal":"Frontiers in immunology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Amivas","companyId":"amivas","modality":"Small molecule","firstApprovalDate":"2020","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":16,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:54.306285+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}